, serve as essential technical guides for restorers of classic Pontiacs. Why We’re Still Talking About It
is a novel, potent, and highly selective inhibitor of CDK11. It demonstrates robust preclinical efficacy in aggressive models of Triple-Negative Breast Cancer through the dual disruption of transcriptional elongation and pre-mRNA splicing. With a favorable pharmacokinetic profile and a wide therapeutic window, HMN-384 warrants further investigation as a first-in-class therapeutic agent. These findings support the initiation of an Investigational New Drug (IND) application and phase I clinical trials for patients with advanced solid tumors. HMN-384